(Q54390371)

English

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. (English)

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

phase II clinical trial

0 references

0 references

9

object named as

Narikazu Boku

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

author name string

Yoon-Koo Kang

1

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

Kei Muro

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

Min-Hee Ryu

3

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

Hirofumi Yasui

4

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

Tomohiro Nishina

5

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

Baek-Yeol Ryoo

6

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

Yukimasa Kamiya

7

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

Shiro Akinaga

8

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

publication date

15 December 2013

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

Investigational New Drugs

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

32

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

355-361

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

https://scigraph.springernature.com/pub.10.1007/s10637-013-0057-2

0 references

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Is there a role for second-line chemotherapy in advanced gastric cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Targeting MET in cancer: rationale and progress

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

MET: a promising anticancer therapeutic target

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Tivantinib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

MET amplification as a potential therapeutic target in gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-0057-2

21 January 2018

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24337769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-Met expression in gastric cancer with liver metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24337769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24337769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24337769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24337769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-013-0057-2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24337769

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54390371&oldid=1777456360"